The service integrates upstream and downstream processes to reduce timelines to GMP production for eligible cell and gene therapy programs.
The facility, slated to be GMP-ready in 2027, will house one of Japan’s largest single-use bioreactor systems for mammalian production, according to the company.
The biopharmaceutical industry’s funding trends, product pipeline, and pace of R&D spending indicate demand is set to improve this year, say William Blair analysts.
AI is helping life sciences manufacturers improve uptime, PM effectiveness, calibration planning, and reliability analysis. See where practical AI adds value in GMP asset management...
The Hangzhou facility achieved licensure just two months after qualification and will hold a total capacity of 172,000 liters upon completion, according to the announcement.
New data from USP reveals that 48 of the 100 vulnerable U.S. medicines are dependent on a key starting material sourced from at least one country.
The engineering campaign validated the company’s expanded mammalian manufacturing suites for late-stage and commercial biologics production at its San Diego site.
The companies said the NMR-based process analytical technology approach could improve scalability and reduce the complexity of RNA vaccine manufacturing.